The company intends to regain compliance with the Exchange's continued listing standards. There can be no assurance that the company will ultimately regain compliance with all applicable Exchange listing standards.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/26/2024 | $13.00 | Buy | B. Riley Securities |
Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, November 7, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in th
Fireside Chat to be held at 3:30pm ET InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Carrie Lachance, President and Chief Operating Officer and Barry Steele, Chief Financial Officer will participate in the Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024. The webcasted fireside chat with CEO, Richard DiIorio will take place at 3:30pm ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference home page at
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, and its joint venture partner Sanara MedTech Inc. ("Sanara"), announced today the execution of an exclusive United States distribution agreement with ChemoMouthpiece, LLC ("ChemoMouthpiece"). Richard DiIorio, InfuSystem's CEO, stated, "Sanara and InfuSystem entered into our partnership in order to bring together our combined technical, operational and commercial strengths to deliver proprietary efficacious products to patients. We believe this exclusive agreement, which bui
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)
SC 13G/A - InfuSystem Holdings, Inc (0001337013) (Subject)
SC 13G - InfuSystem Holdings, Inc (0001337013) (Subject)
Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, November 7, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in th
Record Net Revenues of $33.7 million Representing 6% Growth from the Prior Year Reaffirms Full-Year 2024 Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2024. 2024 Second Quarter Overview: Net revenues totaled $33.7 million, an increase of 6% vs. prior year. Patient Services net revenue was $20.2 million, an increase of 5% vs. prior year. Device Solutions net revenue was $13.5 million, an increase of 8% vs. prior year. Gros
Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, August 8, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in th
B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00
Northland Capital initiated coverage of InfuSystem with a rating of Outperform and set a new price target of $27.00
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has
ROCHESTER HILLS, Michigan, March 02, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Carrie Lachance has been appointed as President in addition to her current role as Chief Operating Officer. Richard DiIorio, chief executive officer of InfuSystem said, “I am pleased to announce the promotion of Carrie Lachance to President of InfuSystem. Carrie has achieved outstanding results exhibiting solid leadership in her role as Chief Operating Officer in managing patient a
8-K - InfuSystem Holdings, Inc (0001337013) (Filer)
8-K - InfuSystem Holdings, Inc (0001337013) (Filer)
8-K - InfuSystem Holdings, Inc (0001337013) (Filer)